November 16, 2016 05:57 AM ESTUpdated 10:03 AM
News Briefing

Bris­tol-My­ers part­ners with En­terome on a gut-lev­el ap­proach to im­muno-on­col­o­gy; Mor­phoSys adds $126M

Shehla Shakoor

Managing Director

Bris­tol-My­ers Squibb has turned to Paris-based mi­cro­bio­me ex­pert En­terome for its lat­est im­muno-on­col­o­gy part­ner­ship. The biotech land­ed a $15 mil­lion up­front and un­spec­i­fied, re­search …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times